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BACKGROUND: Depression has been associated with metabolic alterations, which adversely impact
cardiometabolic health. Here, a comprehensive set of metabolic markers, predominantly lipids, was compared
between depressed and nondepressed persons.
METHODS: Nine Dutch cohorts were included, comprising 10,145 control subjects and 5283 persons with
depression, established with diagnostic interviews or questionnaires. A proton nuclear magnetic resonance metab-
olomics platform provided 230 metabolite measures: 51 lipids, fatty acids, and low-molecular-weight metabolites; 98
lipid composition and particle concentration measures of lipoprotein subclasses; and 81 lipid and fatty acids ratios.
For each metabolite measure, logistic regression analyses adjusted for gender, age, smoking, fasting status, and
lipid-modifying medication were performed within cohort, followed by random-effects meta-analyses.
RESULTS: Of the 51 lipids, fatty acids, and low-molecular-weight metabolites, 21 were significantly related to depression
(false discovery rate q , .05). Higher levels of apolipoprotein B, very-low-density lipoprotein cholesterol, triglycerides,
diglycerides, total and monounsaturated fatty acids, fatty acid chain length, glycoprotein acetyls, tyrosine, and isoleucine
and lower levels of high-density lipoprotein cholesterol, acetate, and apolipoprotein A1 were associated with increased
odds of depression. Analyses of lipid composition indicators confirmed a shift toward less high-density lipoprotein and
more very-low-density lipoprotein and triglyceride particles in depression. Associations appeared generally consistent
across gender, age, and body mass index strata and across cohorts with depressive diagnoses versus symptoms.
CONCLUSIONS: This large-scale meta-analysis indicates a clear distinctive profile of circulating lipid metabolites
associated with depression, potentially opening new prevention or treatment avenues for depression and its
associated cardiometabolic comorbidity.
Keywords: Biomarkers, Cardiovascular, Depression, Metabolites, Metabolomics, Pooled analysis
https://doi.org/10.1016/j.biopsych.2019.08.016Depression imposes a huge burden on individuals and society
(1). With a high annual (6%) and lifetime (19%) prevalence,
depression is among the leading contributors to global disease
burden (1,2). It has been associated with an increased risk of
somatic disease, including cardiometabolic conditions, such
as metabolic syndrome (3), obesity (4), diabetes mellitus (5),
stroke (6), and cardiovascular disease (7), as well as an
increased risk of all-cause mortality (8).
Depression is correlated with metabolic alterations in pe-
ripheral bodily systems (1). A systematic review (9) summarizingN: 0006-3223 Biometabolomics analyses of urine, cerebrospinal fluid, and blood
samples of patients with depression highlighted a set of altered
metabolites implicated in energymetabolism, neuronal integrity,
and transmission. Meta-analyses showed that depression was
associated with increased blood levels of total cholesterol (10)
and triglycerides (TG) (3) and decreased low-density lipoprotein
(LDL) cholesterol (11), high-density lipoprotein (HDL) cholesterol
(3), and u-3 polyunsaturated fatty acids (12). However, consid-
erable heterogeneity was noted between studies, which was
partly explained by differential lipid classifications (11).ª 2019 Society of Biological Psychiatry. 409
logical Psychiatry March 1, 2020; 87:409–418 www.sobp.org/journal
Metabolomics and Depression
Biological
PsychiatryAlterations in circulating lipid concentrations may be linked
to pathophysiological pathways related to depression, such as
chronic activation of the hypothalamic-pituitary-adrenal axis or
chronic low-grade inflammation (1). Glucocorticoid-induced
hypercortisolemia is known to result in lipolysis, the release
of fatty acids and synthesis of very-low-density lipoprotein
(VLDL) (13). Similarly, activation of the proinflammatory
response leads to a reduction in HDL cholesterol and phos-
pholipids and an increase in TG caused by the compensatory
production and accumulation of phospholipid-rich VLDL (14).
In addition, u-3 fatty acids have anti-inflammatory properties,
impact hypothalamic-pituitary-adrenal axis functioning, pro-
mote cell membrane fluidity, and are involved in the regulation
of dopaminergic and serotonergic neurotransmission, which
can be altered in depression (15). Alterations of circulating
concentrations of lipids may also represent a consequence of
depression. Patients with depression are more likely to engage
in unhealthy behaviors, such as sedentariness, excessive
alcohol use, and poor nutrition (with preference for highly
palatable food rich in saturated fats), which may lead to dys-
lipidemia (16) that can result in metabolic syndrome and car-
diovascular disease.
Emerging technologies allow high-throughput profiling of
lipids and other metabolites, which has led to efforts of
determining metabolic signatures of various diseases (17,18).
A few studies have applied this to depression (19,20), but the
results remain inconsistent (21,22); this is partly due to different
methodologies used and different metabolites (lipids, amino
acids, and other small molecules) analyzed (23).
This study aimed to identify plasma lipids, fatty acids, and
low-molecular-weight metabolites associated with depression
by analyzing data from 9 Dutch clinical and population-based
studies and to assess consistency of findings across studies.
A strength of the study is that all metabolites were measured
around the same time with the same targeted proton nuclear
magnetic resonance platform that quantifies lipids, fatty acids,
and low-molecular-weight metabolites, including those that
have been related to consequences of depression [e.g., insulin
resistance (24), onset of cardiovascular events (25), and mor-
tality (26)].METHODS AND MATERIALS
Sample Description
Eleven datasets from 9 cohorts participating in the Biobanking
and BioMolecular resources Research Infrastructure, The
Netherlands (BBMRI-NL) were included: Cohort on Diabetes
and Atherosclerosis Maastricht (CODAM) (27), The Maastricht
Study (28), Erasmus Rucphen Family (ERF) study (29), Leiden
University Migraine Neuro-Analysis (30), Netherlands Epide-
miology of Obesity (NEO) study, Netherlands Study of
Depression and Anxiety (NESDA), Netherlands Twin Register
(31), the Rotterdam Study, and Lifelines DEEP (LLD) (32–34).
Both CODAM and The Maastricht Study contributed 2 data-
sets stratified by diabetes mellitus status. In total, we included
5283 persons with depression and 10,145 control subjects
(see Supplement 1 for detailed cohort descriptions). All par-
ticipants provided written informed consent. Studies were
approved by local ethics committees.410 Biological Psychiatry March 1, 2020; 87:409–418 www.sobp.org/jMeasurements
Depression. The presence of depression was measured
either before blood sampling or up to a maximum of 1 month
after blood sampling. Subjects were defined as cases when
meeting all the criteria required for a diagnosis of major
depressive disorder in clinical structured interviews in 4 co-
horts or when scoring above a validated clinical cutoff score in
depression questionnaires in 5 cohorts (see Table S1 in
Supplement 1 for all instruments and definitions). In the main
analyses, cases included subjects with any history of depres-
sion in lifetime.
Metabolites. Supplement 1 shows details on blood collec-
tion (for each cohort), measurement, and processing of
metabolite measurements. Using targeted high-throughput
proton nuclear magnetic resonance metabolomics (Nightin-
gale Health Ltd., Helsinki, Finland), 230 metabolites or
metabolite ratios were reliably quantified from ethylenediamine
tetraacetate plasma samples (35). This metabolomics platform
has been used in large-scale epidemiological studies of dia-
betes (24), cardiovascular disease (25), mortality (26), and
alcohol intake (36). To enhance interpretation, metabolites
were classified into 3 clusters curated by Nightingale Health
(37): 1) lipids, fatty acids, and low-molecular-weight metabo-
lites (n = 51); 2) lipid composition and particle concentration
measures of lipoprotein subclasses (n = 98); and 3) metabolite
ratios (n = 81). Data were processed according to a shared
protocol applied also in other studies of BBMRI-NL (38). In
each cohort, values of metabolites that could not be quantified
(#5 metabolites per cohort) were set as missing for all sub-
jects. Furthermore, metabolite values in subjects with outlying
concentrations (6 5 SD) were additionally set as missing. A
value of 1 was added to all metabolite values (Supplement 1
includes extensive analyses indicating that the degree of bias
potentially introduced by this transformation is likely negligible)
that were subsequently natural log–transformed to approxi-
mate normality. The obtained values were scaled to standard
deviation units in each cohort to enable comparison.
Statistical Analyses
Per-metabolite logistic regression analyses were initially per-
formed in each dataset. The dependent variable was depres-
sion, and independent variables were the 230 metabolite
measurements. For the Netherlands Twin Register cohort, lo-
gistic regression using generalized estimating equations were
conducted, accounting for family relatedness. All models were
adjusted for age, gender, fasting status, use of lipid-modifying
drugs listed under Anatomical Therapeutic Chemical Classifi-
cation System code C10, and smoking (see Supplement 1 for
measurements). All analyses were based on available data per
metabolite (pairwise deletion). Dataset-specific estimates were
combined using random-effects meta-analyses (restricted
maximum-likelihood estimator) to obtain pooled odds ratios
(ORs). Heterogeneity of results between datasets was quanti-
fied by I2 (39) along with 95% confidence intervals as recom-
mended (40,41).
As body mass index (BMI) has been shown to be associated
with depression (4) and metabolites (42), we reran the main
analyses adjusting for BMI. Furthermore, to investigateournal
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Metabolomics and Depression
Biological
Psychiatrywhether metabolic profiles were dependent on recent pres-
ence of depression, additional analyses were conducted
comparing current depressed cases (depression present 61
month around blood sampling) and controls. We conducted
sensitivity analyses in which we excluded subjects using an-
tidepressant medication (Anatomical Therapeutic Chemical
code N06A) to study the impact of depression apart from its
treatment. Here, we a priori expected to find a less distinctive
metabolomics profile, given that antidepressant medication
prescriptions are more likely in individuals with higher
depression severity. Correlations between estimates obtained
from these sensitivity analyses and estimates obtained in the
main analyses were computed to measure the impact of the
factors considered.
Four additional sets of stratified analysis were performed to
explore whether associations between metabolites and
depression were different as a function of 1) depression
assessment (diagnosis vs. self-report instrument), 2) gender
(men vs. women), 3) age (,50 years vs. $50 years) and 4) BMI
(normal [18.50–24.9] vs. overweight [25.0–29.9] and vs. obesity
[$30]). A Wald test was performed to test differences in effect
sizes across these strata (43), and correlations between esti-
mates obtained across strata were estimated. The false dis-
covery rate (FDR) method (44) was applied to address multiple
testing at the meta-analysis level for 230 metabolites. Meta-
analyses were conducted with the metafor package version
2.0.0 in R version 3.4.2-3.4.3 (R Foundation for Statistical
Computing, Vienna, Austria).T
ab
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RESULTS
Overview of Cohorts
The study population comprised 15,428 adults from 11 data-
sets of 9 cohorts. There were 10,145 control subjects and 5283
participants with depression. Table 1 shows the characteristics
of the 11 datasets. Across the cohorts, the average age ranged
from 40.4 to 64.8 years, the proportion of women ranged from
32% to 70%, and the median prevalence of depression was
29.5%.
Associations of 51 Lipids, Fatty Acids, and Low-
Molecular-Weight Metabolites With Depression
Figure 1 shows a polar plot with ORs of meta-analyses
investigating associations between depression and the 51
metabolites after adjustment for gender, age, smoking, lipid-
modifying drugs, and fasting status. Of these, 21 metabolites
were associated with depression at FDR q , .05 (Table 2;
Figure S1 in Supplement 1). Metabolites associated with a
higher odds for depression were apolipoprotein B; remnant
(non-HDL and non-LDL) cholesterol, VLDL cholesterol, and
mean diameter of VLDL; the glycerides and phospholipid
markers diglycerides; TG in LDL, serum TG, TG in HDL, and TG
in VLDL; the fatty acid measures total fatty acids, mono-
unsaturated fatty acid, and estimated fatty acid chain length;
the inflammation marker glycoprotein acetyls; and the amino
acids tyrosine and isoleucine. Higher levels of metabolites that
were associated with a lower odds for depression were
apolipoprotein A1, cholesterol content for HDL (in particularBiological Psychiatry March 1, 2020; 87:409–418 www.sobp.org/journal 411
Figure 1. Polar plot illustrating pooled odds ratios (OR) and 95% confidence intervals for the association of the 51 lipids, fatty acids and various low-
molecular-weight metabolites with depression. *Significant at false discovery rate q , .05. Dotted circle indicates an OR of 1. Density: high-density lipo-
protein (HDL) subfraction 2 (HDL2), 1.063–1.125 g/mL; HDL3, 1.125–1.210 g/mL. AcAce, acetoacetate; Ace, acetate; Ala, alanine; Alb, albumin; ApoA1,
apolipoprotein A-I; ApoB, apolipoprotein B; bOHBut, 3-hydroxybutyrate; C, cholesterol; Cit, citrate; CLA, conjugated linoleic acids; Crea, creatinine; D, mean
diameter; DAG, diglycerides; DHA, docosahexaenoic acid; Est, esterified; FA, fatty acids; FALen, estimated fatty acids chain length; FAw3, u-3 fatty acids;
FAw6, u-6 fatty acids; Glc, glucose; Gln, glutamine; Gp, glycoprotein acetyls, mainly a1-acid glycoprotein; His, histidine; IDL, intermediate-density lipoprotein;
Ile, isoleucine; LA, linoleic acid (18:2); Lac, lactate; Leu, leucine; LDL, low-density lipoprotein; MUFA, monounsaturated fatty acids (16:1, 18:1); PC, phos-
phatidylcholine and other cholines; Phe, phenylalanine; PUFA, polyunsaturated fatty acids; Remnant, non-HDL, non-LDL cholesterol; SFA, saturated fatty
acids; SM, sphingomyelins; TG, triglycerides; TotCho, total cholines; TotFA, total fatty acids; TotPG, total phosphoglycerides; Tyr, tyrosine; UnsatDeg,
estimated degree of unsaturation; Val, valine; VLDL, very-low-density lipoprotein.
Metabolomics and Depression
Biological
PsychiatryHDL2 and HDL3 cholesterol) and mean diameter of HDL, and
ketone body acetate.
Heterogeneity was small (I2 ,25% for 15 of 21 metabolites)
and statistically nonsignificant in almost all (19 of 21) analyses.
As shown in the related forest plots (Figure S1 in Supplement 1),
association estimates were quite consistent across the
different datasets, including the datasets enriched for car-
diometabolic risk. To confirm this, we reran the analyses after
removing 2 datasets (CODAM subgroup with type 2 diabetes
mellitus and The Maastricht Study subgroup with type 2 dia-
betes mellitus) containing approximately 900 participants with
established diabetes and elevated cardiovascular risk factors.
Association estimates were highly concordant with estimates
of the original analyses (r = .99); all 21 metabolites detected in
the original analyses were associated at nominal level with
depression (17 at FDR q , .05) (Table S3 in Supplement 1).
Additional adjustment for BMI partially reduced the strength
of the association of these 21 metabolites with depression412 Biological Psychiatry March 1, 2020; 87:409–418 www.sobp.org/j(regression slope of the 21 b values before vs. after BMI
adjustment = .65, whereas a b value of 1 would indicate similar
average association sizes; correlation r = .98): of the 21 me-
tabolites associated with depression, 16 remained significantly
related to depression at p , .05 and 13 at FDR q , .05
(Table 2). Table S2 in Supplement 2 shows the pooled ORs and
heterogeneity findings for all metabolites.
Associations of 98 Detailed Lipid Composition and
Particle Concentration Measures of Lipoprotein
Subclasses With Depression
Figure 2 shows the ORs of the meta-analyses for the 98 lipid
measures of the 14 lipoprotein subclasses, ordered from large
to small particle size. Generally, there appeared to be a shift in
association with depression by lipoprotein classes: VLDL levels
were positively related to depression, intermediate-density
lipoprotein and LDL levels were not consistently associated,ournal
Table 2. Overview of 21 Lipids, Fatty Acids, and Various Low-Molecular-Weight Metabolites That Are Significantly Related to
Depression in Pooled Analysis at FDR q , .05
Metabolite
Model 1 Model 2
Pooled OR p Value FDR q Value Pooled OR p Value FDR q Value
Apolipoproteins
Apolipoprotein A1 0.90 2.71 3 1027 2.50 3 1026 0.94 .007 .021
Apolipoprotein B 1.08 2.40 3 1024 6.90 3 1024 1.05 .014 .040
Cholesterol
Remnant cholesterol 1.07 .003 .006 1.05 .014 .038
VLDL cholesterol 1.10 1.68 3 1024 5.03 3 1024 1.07 .001 .002
HDL cholesterol 0.86 1.24 3 10212 9.47 3 10211 0.91 2.03 3 1025 2.59 3 1024
HDL2 cholesterol 0.89 5.78 3 10
26 2.79 3 1025 0.93 .001 .003
HDL3 cholesterol 0.90 2.18 3 10
25 8.37 3 1025 0.93 4.91 3 1024 .002
Mean diameter of VLDL 1.13 1.30 3 1026 8.82 3 1026 1.08 2.39 3 1024 .001
Mean diameter of HDL 0.91 2.10 3 1024 6.10 3 1024 0.96 .104 .222
Diglycerides and Triglycerides
Diglycerides 1.09 2.56 3 1025 9.65 3 1025 1.07 .003 .008
Serum total TG 1.11 3.29 3 1025 1.15 3 1024 1.08 1.92 3 1024 .001
VLDL TG 1.11 8.68 3 1025 2.77 3 1024 1.08 1.76 3 1024 .001
LDL TG 1.05 .015 .032 1.04 .101 .218
HDL TG 1.09 .007 .015 1.07 .029 .072
Fatty Acids
Monounsaturated FA 1.09 7.13 3 1026 3.35 3 1025 1.06 .004 .012
Total FA 1.05 .013 .027 1.03 .102 .219
Estimated FA chain length 1.10 .020 .043 1.08 .060 .140
Inflammation
Glycoprotein acetyls 1.13 .003 .007 1.09 .028 .071
Ketone Bodies
Acetate 0.91 .003 .006 0.93 .038 .092
Amino Acids
Tyrosine 1.07 .013 .028 1.02 .552 .760
Isoleucine 1.14 8.26 3 1026 3.71 3 1025 1.08 .001 .004
Model 1 was adjusted for gender, age, smoking, lipid-modifying drugs, and fasting status; model 2 was adjusted for model 1 and body mass
index.
FA, fatty acids; FDR, false discovery rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio; TG, triglycerides; VLDL,
very-low-density lipoprotein.
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Psychiatrywhereas HDL measures were inversely related to depression.
Furthermore, depression was related to higher TG levels.
Associations of 81 Metabolite Ratios With
Depression
Figure S2 in Supplement 1 shows the ORs of the meta-analyses
for the 81 metabolite ratios, of which 27 were significant at
FDR q, .05. In general, TG-to-total lipid ratios were significantly
related to an increased odds of depression. Some of the VLDL,
intermediate-density lipoprotein, LDL, and HDL measures as
percentage of total lipids were positively related to depression,
whereas otherswere inversely related. In general, associations of
the metabolite ratios with depression were less pronounced
compared with those with absolute metabolite values.
Sensitivity Analyses
Current Depression. The original 5283 depression cases
included subjects with any lifetime history of depression. In
62% of the cases (3265 subjects), depression was presentBiological Pbetween 1 month before and 1 month after blood draw. We
repeated analyses with only these 3265 current cases with
depression (vs. 10,145 controls). Of the 51 lipids, fatty acids,
and low-molecular-weight metabolites, 22 were associated
with current depression at FDR q , .05 (Figure S3 in
Supplement 1). Notably, the strength of the associations with
the 51 metabolites tended to be greater for current depression
than for the original definition (regression slope of b values for
current vs. broadly defined depression = 1.22, r = .95)
(Table S2 in Supplement 2). Table S2 in Supplement 2 and
Figures S4 and S5 in Supplement 1 show associations of the
98 lipid measures of lipoprotein subclasses and the 81
metabolite ratios with current depression, which were largely in
line with those of original analyses.
Antidepressant Medication. To study whether associa-
tions were independent of concurrent antidepressant medi-
cation use, we removed 1597 subjects across cohorts who
reported use of antidepressants. The majority were depressionsychiatry March 1, 2020; 87:409–418 www.sobp.org/journal 413
Figure 2. Pooled odds ratios (OR) and 95% confidence intervals for the association of the 98 lipid measures of lipoprotein subclasses with depression.
*Significant at false discovery rate q, .05. Dotted circle indicates an OR of 1. Particle sizes: extremely large (XXL) very-low-density lipoprotein (VLDL),.75 nm;
very large (XL) VLDL, 64 nm; large (L) VLDL, 53.6 nm; medium (M) VLDL, 44.5 nm; small (S) VLDL, 36.8 nm; very small (XS) VLDL, 31.3 nm; intermediate-density
lipoprotein (IDL), 28.6 nm; L low-density lipoprotein (LDL), 25.5 nm; M LDL, 23.0 nm; S LDL, 18.7 nm; XL high-density lipoprotein (HDL), 14.3 nm; L HDL, 12.1
nm; M HDL, 10.9 nm; S HDL, 8.7 nm. C, total cholesterol; CE, cholesterol ester; FC, free cholesterol; L, total lipids; P, particle concentration; PL, phospholipids;
TC, triglycerides.
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Psychiatrycases (n = 1305), which was expected given that depression is
the main indication for receiving antidepressant treatment.
Additionally, one study (LLD) was removed because of model
convergence issues. In the remaining 3966 cases and 8887
controls, representing a 21% decrease in effective sample size
compared with the original analyses, associations with the 51
lipids, fatty acids, and low-molecular-weight metabolites were
generally in the same direction, but the strength of the asso-
ciations was attenuated (regression slope of b values before
and after exclusion of antidepressant users = .60, r = .88)
(Figure S6 in Supplement 1). Among the 21 significantly414 Biological Psychiatry March 1, 2020; 87:409–418 www.sobp.org/jassociated metabolites in the overall sample, 8 were still
associated at p , .05, of which 2 (HDL3 cholesterol and ace-
tate) at FDR q , .05 in the antidepressant-free subsample.
Subgroups. Exploration of consistency of associations
across subgroups showed that there were no significant dif-
ferences (Wald test, FDR q . .05) in the strength of the as-
sociation between metabolites and depression across
subgroups with depression diagnoses versus self-reported
depression (r = .75) (Figure S7 in Supplement 1), across men
versus women (r = .64) (Figure S8 in Supplement 1), across ageournal
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Psychiatry,50 years versus$50 years (r = .84) (Figure S9 in Supplement 1),
and across BMI groups (normal vs. overweight [r = .68], normal
vs. obese [r = .55], overweight vs. obese [r = .71])
(Figures S10–S12 in Supplement 1).DISCUSSION
This meta-analysis of metabolomics and depression is, to our
knowledge, the largest of its kind. We analyzed data of more
than 15,000 subjects from 9 Dutch clinical and population-
based studies in the Netherlands to identify metabolites
associated with depression. Our findings showed that
depression is associated with a metabolic signature toward
less HDL and more VLDL and TG particles. More specifically,
21 plasma lipids, fatty acids, and low-molecular-weight me-
tabolites were significantly related to depression: higher levels
of apolipoprotein B, VLDL cholesterol, TG, diglycerides, total
and monounsaturated fatty acids, fatty acid chain length,
glycoprotein acetyls, tyrosine, and isoleucine, and lower levels
of HDL cholesterol, acetate, and apolipoprotein A1. Associa-
tions were generally consistent across gender, age, and BMI
strata and across cohorts using depression diagnoses versus
depressive symptoms. These metabolic alterations in depres-
sion could potentially explain part of the increased risk of
cardiometabolic disease in individuals with depression.
Our findings that depression is related to higher VLDL, higher
TG, and lower HDL are in line with previous research (3,11,45). In
the present study, we predominantly found differences in abso-
lute lipid measures of the VLDL subfractions, whereas findings
with lipid measures to lipid ratios in VLDL were less consistently
associated with depression. This suggests that the total amount
of lipids, rather than the type of lipids, is the main contributor to
associations of depression with VLDL. For other metabolites,
previous studies indicated more mixed findings. We did not find
associations for LDL cholesterol measures, which contrasts with
a previous meta-analysis that showed associations between
depression and increased LDL cholesterol (11). For measures of
fatty acids, we observed that higher monounsaturated fatty
acids, total fatty acids, and estimated fatty acids chain length
were associated with an increased odds of depression. Most
evidence for links with fatty acids in depression stems from
research on u-3 fatty acids (12), for which we did not observe a
consistent, significant association with depression in the present
study. The finding of proinflammatory glycoprotein acetyls being
positively associated with depression is in line with the large
body of evidence linking inflammation to depression (46). The
short chain fatty acid and ketone body acetate was lower in
depression. It was hypothesized that a Western-style diet alters
gut microbiome composition, resulting in lower acetate levels,
which could subsequently induce depression (4). Furthermore, a
smaller study found lower isoleucine levels in depression (47),
which contrasts our findings. Finally, a review concluded that
there was no association between tyrosine and depression (48),
whereas we observed higher tyrosine in depression. Discrep-
ancies could be explained by differences in study characteristics
or variation in analytic approaches, such as selection of poten-
tially confounding factors.
We additionally evaluated the impact of the time frame of
depression assessment on the results. In secondary analyses,
including cases with current depression only, associationsBiological Ptended to become enhanced, suggesting that metabolomics
alterations represent state markers reflecting current depres-
sion. Nevertheless, a similar profile of associations was found
when analyzing depression cases defined in a broader time
frame. The metabolic signature identified may therefore also
represent a persisting biological scar after remission of
depression or a preexisting underlying vulnerability factor for
development of depression.
The impact of antidepressant medication use on the results
was explored in secondary analyses, although this observa-
tional study precludes definitive conclusions, as depression
severity most likely represents the clinical indication for anti-
depressant treatment (confounded by indication) (49). We
reanalyzed data after excluding antidepressant users and
found that the strength of associations was attenuated.
Furthermore, the reduction in effective sample size substan-
tially impacted the power to find significant associations.
Nevertheless, directions of associations were highly consistent
with those obtained in the full sample. Furthermore, the liter-
ature shows that potential detrimental effects of antidepres-
sants on dyslipidemia is evident mainly for tricyclic
antidepressants (50,51). Data from the NESDA cohort (51),
including patients from mental health care institutions and with
the highest prevalence of antidepressant users (27%) (Table 1),
showed that tricyclic antidepressants were prescribed only in
3% of the participants. As the overall prevalence of antide-
pressant use in other cohorts included in the present meta-
analysis was lower than approximately 9%, it could be
assumed that the number of users of tricyclic antidepressants
may be limited. This observation, combined with the results of
our sensitivity analyses, suggests that antidepressant use is
unlikely to be the major driver of the associations between
metabolites and depression.
Secondary analyses also indicated that results were generally
attenuated when BMI was taken into account, suggesting that
part of the differential metabolite levels in depression could be
explained by BMI. However, interrelationships between BMI,
metabolites, depression, and antidepressants are particularly
complex. A significant genetic correlation has been found be-
tween depression and BMI (52), indicating that they may emerge
from partially shared etiological mechanisms; at the same time,
BMI has been shown to influence metabolite concentrations (42).
The ability to disentangle different independent effects of this
complex network in observational data is limited. Nevertheless,
the majority of metabolites were associated with depression after
taking into account BMI, indicating that this factor explains only a
limited portion of the depression-metabolites link.
The present findings may be explained by 3 non–mutually
exclusive scenarios. First, alterations of lipids may be a
consequence of depression. Depressed persons are more
likely to engage in unhealthy behaviors, such as sedentariness,
excessive alcohol use, and poor nutrition (e.g., saturated fats),
which may lead to dyslipidemia (16). Second, lipid dysregula-
tions may be part of the pathophysiological pathways
implicated in depression, such as chronic hypothalamic-
pituitary-adrenal axis and inflammatory activity, resulting in
lipolysis, release of fatty acids, synthesis of VLDL, hyper-
triglyceridemia, and reduction in HDL cholesterol. Third,
metabolomic alterations in depression may represent epiphe-
nomena stemming from the same root, such as a commonsychiatry March 1, 2020; 87:409–418 www.sobp.org/journal 415
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Psychiatrygenetic factor. A recent genome-wide association study of major
depression involving .450,000 participants reported a signifi-
cant genetic correlation (rg = .14, p = 7.8 3 10
27) with high TG
levels, but not with LDL or HDL (53). Furthermore, no genetic
correlations emerged with metabolites of the same panel that we
found to be associated with depression, although the relatively
smaller sample size (approximately 25,000) of the metabolomics
genome-wide association study may substantially limit the ability
to detect correlations; the only exception was a nominally sig-
nificant correlation with glycoprotein acetyls (rg = .15, p = .03),
with the same direction of the phenotypic association we iden-
tified. Further experimental studies and genetically informed
designs such as Mendelian randomization may disentangle
whether depression and lipid dysregulations emerge from shared
etiology and whether depression causally determines lipid alter-
ations or vice versa.
The present study has some limitations. Owing to limited
availability or differences in assessment across datasets, we
cannot rule out confounding by other health-related or lifestyle
factors, such as chronic cardiometabolic conditions, alcohol
use, or specific food intake before sample collection. Never-
theless, the associations between depression and metabolites
were consistent across datasets, including those enriched for
traits such as diabetes, cardiovascular risk factors, and
migraine. Furthermore, alcohol use may represent a mediating
mechanism rather than a confounder in the metabolites-
depression association, as recent evidence (54) showed that
alcohol dependence is to quite some extent caused by
depression. Analyses were adjusted for fasting status (.94%
of subjects were fasting) (Table 1), but both fasting and non-
fasting samples can be reliably analyzed by the metabolomics
platform used (26,35). We could not examine whether the as-
sociations with metabolites detected vary as a function of
specific depression clinical characteristics. Strengths of the
study (large samples, metabolites data generated for all
studies with the same platform) have enabled the identification
of the most reliable metabolic signals associated with
depression. These are worth further examination in relation to
clinically relevant phenotypes (e.g., age of onset, recurrence,
duration, symptom profiles) in future studies based on psy-
chiatrically well-characterized samples.
This large-scale meta-analysis including more than 15,000
participants identified a metabolomics signature associated
with depression. This biological signature is partially shared
with other conditions, such as diabetes, obesity, and cardio-
vascular diseases (3,5–7) that commonly co-occur with
depression, heavily burdening public health resources. Alter-
ations in the lipid spectrum identified in the present study may
represent a substrate linking depression to cardiometabolic
diseases and therefore a potential target for prevention and
treatment of depression and its detrimental somatic sequelae.ACKNOWLEDGMENTS AND DISCLOSURES
This work was performed within the framework of the BBMRI Metabolomics
Consortium funded by BBMRI-NL, a research infrastructure financed by the
Dutch government through Netherlands Organisation for Scientific Research
(NWO) (Grant Nos. 184.021.007 and 184033111).
NESDA: The infrastructure for the NESDA study (www.nesda.nl) is fun-
ded through the Geestkracht program of the Netherlands Organisation for416 Biological Psychiatry March 1, 2020; 87:409–418 www.sobp.org/jHealth Research and Development (Grant No. 10-000-1002) and financial
contributions by participating universities and mental health care organiza-
tions (VU University Medical Center, GGZ inGeest, Leiden University Med-
ical Center, Leiden University, GGZ Rivierduinen, University Medical Center
Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe,
Rob Giel Onderzoekscentrum).
CODAM: The initiation of the CODAM study was supported by NWO
(Grant No. 940-35-034) and the Dutch Diabetes Research Foundation (Grant
No. 98.901). The work of NV was supported through a grant from the
Maastricht University Medical Center1.
Leiden University Migraine Neuro-Analysis: Leiden University Migraine
Neuro-Analysis is supported by the Netherlands Organisation for Health
Research and Development (Vidi Grant No. 91711319 [to GMT]), Centre for
Medical Systems Biology and Netherlands Consortium for Systems Biology,
both within the framework of the Netherlands Genomics Initiative/NWO (to
AMJMvdM), and Seventh Framework Programme EU project EURO-
HEADPAIN (Grant No. 602633 [to AMJMvdM and GMT]).
NEO study: The NEO study is supported by the participating De-
partments, Division, and Board of Directors of the Leiden University Medical
Center, and by the Leiden University, Research Profile Area Vascular and
Regenerative Medicine. DOM-K is supported by Dutch Science Organiza-
tion (ZonMW-VENI Grant No. 916.14.023).
The Maastricht Study: The Maastricht Study was supported by the Eu-
ropean Regional Development Fund via OP-Zuid, Province of Limburg,
Dutch Ministry of Economic Affairs (Grant No. 31O.041), Stichting De Wei-
jerhorst, Pearl String Initiative Diabetes, Cardiovascular Center, Cardiovas-
cular Research Institute Maastricht, School for Public Health and Primary
Care, School for Nutrition, Toxicology and Metabolism, Stichting Annadal,
and Health Foundation Limburg and by unrestricted grants from Janssen-
Cilag B.V., Novo Nordisk Farma B.V., and Sanofi-Aventis Netherlands B.V.
Netherlands Twin Register: Funding was obtained from the NWO and
MagW/ZonMW (Grant Nos. 904-61-090, 985-10-002, 904-61-193,480-04-
004, l400-05-717, Addiction-31160008, Middelgroot-911-09-032, Spino-
zapremie 56-464-14192), BBMRI-NL (Grant No. 184.021.007), European
Community’s Seventh Framework Programme (2007–2013) ENGAGE
(HEALTH-F4-2007-201413), European Science Council (ERC Advanced
Grant No. 230374), Rutgers University Cell and DNA Repository (National
Institute of Mental Health Grant No. U24 MH068457-06), Avera Institute, and
National Institutes of Health (Grant Nos. R01D0042157-01A and MH081802,
Grand Opportunity Grant No. 1RC2 MH089951). We gratefully acknowledge
NWO Grant No. 480-15-001/674: Netherlands Twin Register Repository:
researching the interplay between genome and environment.
ERF: The ERF study as a part of European Special Populations Research
Network was supported by European Commission FP6 STRP Grant No.
018947 (LSHG-CT-2006-01947) and received funding from the European
Community’s Seventh Framework Programme (2007–2013) HEALTH-F4-
2007-201413 by the European Commission under the program “Quality of
Life and Management of the Living Resources” of Fifth Framework Pro-
gramme (Grant No. QLG2-CT-2002-01254). High-throughput analysis of the
ERF data was supported by a joint grant from NWO and the Russian
Foundation for Basic Research (Grant No. 047.017.043).
Rotterdam Study: The Rotterdam Study is funded by Erasmus Medical
Center and Erasmus University, Rotterdam, Netherlands Organisation for
the Health Research and Development, Research Institute for Diseases in
the Elderly, Ministry of Education, Culture and Science, Ministry for Health,
Welfare and Sports, European Commission (DG XII), and Municipality of
Rotterdam.
LLD study: LLD is a subcohort of the Lifelines cohort study, with addi-
tional measurements and sample collection funded by CardioVasculair
Onderzoek Nederland (Grant No. 2012-03), European Science Council
(Grant No. 715772 [to AZ]), and NWO (Vidi Grant No. 016.178.056 [to AZ]
and Grant No. 864.13.013 [to JF]. SG holds scholarships from the Graduate
School of Medical Sciences, University of Groningen.
See Supplement 1 for BBMRI-NL Metabolomics Consortium collabora-
tors and their affiliations.
We thank the BBMRI-NL Metabolomics Consortium (see Supplement 1).
The authors of the NEO study thank all participants, all participating
general practitioners for inviting eligible participants, all research nurses
for data collection, and the NEO study group: Pat van Beelen, Petraournal
Metabolomics and Depression
Biological
PsychiatryNoordijk, and Ingeborg de Jonge for coordination, laboratory, and data
management.
The authors of the ERF study thank all study participants and their rel-
atives; general practitioners and neurologists for their contributions; and P.
Veraart for help in genealogy, J. Vergeer for supervision of the laboratory
work, and P. Snijders for help in data collection.
The authors of the Rotterdam Study thank the study participants, the
staff from the Rotterdam Study, and the participating general practitioners
and pharmacists.
DOM-K works as a part-time clinical research consultant for Metabolon,
Inc. BWJHP received (nonrelated) research funding from Janssen Research
and Boehringer. All other authors report no biomedical financial interests or
potential conflicts of interest.ARTICLE INFORMATION
From the Department of Psychiatry (MBo, YM, CST, BWJHP), Amsterdam
Public Health Research Institute and Amsterdam Neuroscience, Amsterdam
UMC, and Department of Biological Psychology (RP, LL, DIB), Amsterdam
Public Health Research Institute, Vrije Universiteit, Amsterdam; Departments
of Clinical Epidemiology (TA-S, DOM-K, RdM), Neurology (AMJMvdM, GMT,
GLJO), Human Genetics (AMJMvdM, LSV, KWvD), Molecular Epidemiology
(MBe, PES), and Endocrinology (KWvD), Leiden University Medical Center,
Leiden; Departments of Epidemiology (NA, AD, CvD, HT) and Human Ge-
netics (AD), Erasmus University Medical Center, Rotterdam; Departments of
Genetics (SG, JF, AZ) and Pediatrics (JF), University Medical Center Gro-
ningen, Groningen; Departments of Epidemiology (NV, ICWA), Internal
Medicine (MvG, MTS, ICWA, CJHvdK, CDAS), and Psychiatry and Neuro-
psychology (SK), Cardiovascular Research Institute Maastricht (NV, MvG,
MTS, ICWA, CJHvdK, CDAS), Maastricht Center for Systems Biology (NV,
ICWA), and School for Mental Health and Neuroscience (SK), Maastricht
University, Maastricht, The Netherlands.
MBo and YM contributed equally to this work.
Address correspondence to Mariska Bot, Ph.D., Department of Psychi-
atry, Amsterdam UMC, Vrije Universiteit Amsterdam, Oldenaller 1, Amster-
dam 1081 HJ, The Netherlands; E-mail: m.bot@ggzingeest.nl.
Received Mar 5, 2019; revised and accepted Aug 19, 2019.
Supplementary material cited in this article is available online at https://
doi.org/10.1016/j.biopsych.2019.08.016.REFERENCES
1. Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al.
(2016): Major depressive disorder. Nat Rev Dis Prim 2:16065.
2. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C,
et al. (2012): Disability-adjusted life years (DALYs) for 291 diseases and
injuries in 21 regions, 1990-2010: A systematic analysis for the Global
Burden of Disease Study 2010. Lancet 380:2197–2223.
3. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, Hu FB
(2012): Bidirectional association between depression and metabolic
syndrome: A systematic review and meta-analysis of epidemiological
studies. Diabetes Care 35:1171–1180.
4. Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW (2019):
Depression and obesity: Evidence of shared biological mechanisms.
Mol Psychiatry 24:18–33.
5. Mezuk B, Eaton WW, Albrecht S, Golden SH (2008): Depression and
type 2 diabetes over the lifespan: A meta-analysis. Diabetes Care
31:2383–2390.
6. Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB (2011): Depression and
risk of stroke morbidity and mortality: A meta-analysis and systematic
review. JAMA 306:1241–1249.
7. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C,
Beekman A (2007): Depression and the risk for cardiovascular dis-
eases: Systematic review and meta analysis. Int J Geriatr Psychiatry
22:613–626.
8. Cuijpers P, Vogelzangs N, Twisk J, Kleiboer A, Li J, Penninx BW
(2014): Comprehensive meta-analysis of excess mortality in depres-
sion in the general community versus patients with specific illnesses.
Am J Psychiatry 171:453–462.Biological P9. Macdonald K, Trakadis Y (2019): Biomarkers for major depressive and
bipolar disorders using metabolomics: A systematic review. Am J Med
Genet B Neuropsychiatr Genet 180:122–137.
10. Shin JY, Suls J, Martin R (2008): Are cholesterol and depression
inversely related? A meta-analysis of the association between two
cardiac risk factors. Ann Behav Med 36:33–43.
11. Persons JE, Fiedorowicz JG (2016): Depression and serum low-
density lipoprotein: A systematic review and meta-analysis. J Affect
Disord 206:55–67.
12. Lin PY, Huang SY, Su KP (2010): A meta-analytic review of poly-
unsaturated fatty acid compositions in patients with depression. Biol
Psychiatry 68:140–147.
13. Fardet L, Fève B (2014): Systemic glucocorticoid therapy: A review of
its metabolic and cardiovascular adverse events. Drugs 74:1731–
1745.
14. Esteve E, Ricart W, Fernández-Real JM (2005): Dyslipidemia
and inflammation: An evolutionary conserved mechanism. Clin Nutr
24:16–31.
15. Grosso G, Galvano F, Marventano S, Malaguarnera M, Bucolo C,
Drago F, Caraci F (2014): Omega-3 fatty acids and depression: Sci-
entific evidence and biological mechanisms. Oxid Med Cell Longev
2014:313570.
16. Mensink RP, Zock PL, Kester ADM, Katan MB (2003): Effects of dietary
fatty acids and carbohydrates on the ratio of serum total to HDL
cholesterol and on serum lipids and apolipoproteins: A meta-analysis
of 60 controlled trials. Am J Clin Nutr 77:1146–1155.
17. Quinones MP, Kaddurah-Daouk R (2009): Metabolomics tools for
identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis
35:165–176.
18. GAN Gowda, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D (2008):
Metabolomics-based methods for early disease diagnostics: A review.
Expert Rev Mol Diagn 8:617–633.
19. Shao W, Chen J, Fan S, Lei Y, Xu H, Zhou J, et al. (2015): Combined
metabolomics and proteomics analysis of major depression in an
animal model: Perturbed energy metabolism in the chronic mild
stressed rat cerebellum. OMICS 19:383–392.
20. Zheng H, Zheng P, Zhao L, Jia J, Tang S, Xu P, et al. (2017): Predictive
diagnosis of major depression using NMR-based metabolomics and
least-squares support vector machine. Clin Chim Acta 464:223–227.
21. Martins-de-Souza D (2014): Proteomics, metabolomics, and protein
interactomics in the characterization of the molecular features of major
depressive disorder. Dialogues Clin Neurosci 16:63–73.
22. Guest PC, Guest FL, Martins-de Souza D (2016): Making sense of
blood-based proteomics and metabolomics in psychiatric research.
Int J Neuropsychopharmacol 19:1–10.
23. Gadad BS, Jha MK, Czysz A, Furman JL, Mayes TL, Emslie MP,
Trivedi MH (2018): Peripheral biomarkers of major depression and
antidepressant treatment response: Current knowledge and future
outlooks. J Affect Disord 233:3–14.
24. Würtz P, Mäkinen VP, Soininen P, Kangas AJ, Tukiainen T, Kettunen J,
et al. (2012): Metabolic signatures of insulin resistance in 7,098 young
adults. Diabetes 61:1372–1380.
25. Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D,
Tillin T, et al. (2015): Metabolite profiling and cardiovascular event risk:
A prospective study of 3 population-based cohorts. Circulation
131:774–785.
26. Fischer K, Kettunen J, Würtz P, Haller T, Havulinna AS, Kangas AJ,
et al. (2014): Biomarker profiling by nuclear magnetic resonance
spectroscopy for the prediction of all-cause mortality: An observa-
tional study of 17,345 persons. PLoS Med 11:e1001606.
27. van Greevenbroek MMJ, Jacobs M, van der Kallen CJH,
Vermeulen VMMJ, Jansen EHJM, Schalkwijk CG, et al. (2011): The
cross-sectional association between insulin resistance and circulating
complement C3 is partly explained by plasma alanine aminotrans-
ferase, independent of central obesity and general inflammation (the
CODAM study). Eur J Clin Invest 41:372–379.
28. Schram MT, Sep SJS, Van Der Kallen CJ, Dagnelie PC, Koster A,
Schaper N, et al. (2014): The Maastricht Study: An extensive pheno-
typing study on determinants of type 2 diabetes, its complications and
its comorbidities. Eur J Epidemiol 29:439–451.sychiatry March 1, 2020; 87:409–418 www.sobp.org/journal 417
Metabolomics and Depression
Biological
Psychiatry29. Sayed-Tabatabaei FA, Van Rijn MJE, Schut AFC, Aulchenko YS,
Croes EA, Zillikens MC, et al. (2005): Heritability of the function and
structure of the arterial wall: Findings of the Erasmus Rucphen Family
(ERF) study. Stroke 36:2351–2356.
30. van Oosterhout W, Weller C, Stam A, Bakels F, Stijnen T, Ferrari M,
Terwindt G (2011): Validation of the web-based LUMINA ques-
tionnaire for recruiting large cohorts of migraineurs. Cephalalgia
31:1359–1367.
31. Boomsma DI, Geus EJC de, Vink JM, Stubbe JH, Distel MA,
Hottenga J-J, et al. (2006): Netherlands Twin Register: From twins to
twin families. Twin Res Hum Genet 9:849–857.
32. Scholtens S, Smidt N, Swertz MA, Bakker SJL, Dotinga A, Vonk JM,
et al. (2015): Cohort profile: LifeLines, a three-generation cohort study
and biobank. Int J Epidemiol 44:1172–1180.
33. Tigchelaar EF, Bonder MJ, Jankipersadsing SA, Fu J, Wijmenga C,
Zhernakova A (2016): Gut microbiota composition associated with
stool consistency. Gut 65:540–542.
34. Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M,
Vatanen T, et al. (2016): Population-based metagenomics analysis
reveals markers for gut microbiome composition and diversity. Sci-
ence 352:565–569.
35. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M (2015):
Quantitative serum nuclear magnetic resonance metabolomics in
cardiovascular epidemiology and genetics. Circ Cardiovasc Genet
8:192–206.
36. Würtz P, Cook S, Wang Q, Tiainen M, Tynkkynen T, Kangas AJ, et al.
(2016): Metabolic profiling of alcohol consumption in 9778 young
adults. Int J Epidemiol 45:1493–1506.
37. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-
Korpela M (2017): Quantitative serum nuclear magnetic resonance
metabolomics in large-scale epidemiology: A primer on -omic tech-
nologies. Am J Epidemiol 186:1084–1096.
38. Onderwater GLJ, Ligthart L, Bot M, Demirkan A, Fu J, Kallen CJH van
der, et al. (2019): Large-scale plasma metabolome analysis reveals
alterations in HDL metabolism in migraine. Neurology 92:e1899–
e1911.
39. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003): Measuring
inconsistency in meta-analyses. BMJ 327:557–560.
40. Viechtbauer W (2007): Confidence intervals for the amount of hetero-
geneity in meta-analysis. Stat Med 26:37–52.
41. Ioannidis JPA, Patsopoulos NA, Evangelou E (2007): Uncertainty in
heterogeneity estimates in meta-analyses. BMJ 335:914.
42. Würtz P, Wang Q, Kangas AJ, Richmond RC, Skarp J, Tiainen M, et al.
(2014): Metabolic signatures of adiposity in young adults: Mendelian418 Biological Psychiatry March 1, 2020; 87:409–418 www.sobp.org/jrandomization analysis and effects of weight change. PLoS Med 11:
e1001765.
43. Viechtbauer W: Comparing estimates of independent meta-analyses or
subgroups. Available at: http://www.metafor-project.org/doku.php/tips:
comp_two_independent_estimates. Accessed November 27, 2017.
44. Benjamini Y, Hochberg Y (1995): Controlling the false discovery rate: A
practical and powerful approach to multiple testing. J R Stat Soc B
57:289–300.
45. Segoviano-Mendoza M, Cárdenas-de la Cruz M, Salas-Pacheco J,
Vázquez-Alaniz F, La Llave-León O, Castellanos-Juárez F, et al. (2018):
Hypocholesterolemia is an independent risk factor for depression
disorder and suicide attempt in Northern Mexican population. BMC
Psychiatry 18:7.
46. Kiecolt-Glaser JK, Derry HM, Fagundes CP (2015): Inflammation:
Depression fans the flames and feasts on the heat. Am J Psychiatry
172:1075–1091.
47. Baranyi A, Amouzadeh-Ghadikolai O, von Lewinski D,
Rothenhäusler H-B, Theokas S, Robier C, et al. (2016): Branched-
chain amino acids as new biomarkers of major depression—a novel
neurobiology of mood disorder. PLoS One 11:e0160542.
48. Parker G, Brotchie H (2011): Mood effects of the amino acids trypto-
phan and tyrosine. Acta Psychiatr Scand 124:417–426.
49. Kyriacou DN, Lewis RJ (2016): Confounding by indication in clinical
research. JAMA 316:1818–1819.
50. Mcintyre RS, Park KY, Law CWY, Sultan F, Adams A, Lourenco MT,
et al. (2010): The association between conventional antidepressants
and the metabolic syndrome: A review of the evidence and clinical
implications. CNS Drugs 24:741–753.
51. Van Reedt Dortland AK, Giltay EJ, Van Veen T, Zitman FG,
Penninx BW (2010): Metabolic syndrome abnormalities are associated
with severity of anxiety and depression and with tricyclic antidepres-
sant use. Acta Psychiatr Scand 122:30–39.
52. Milaneschi Y, Lamers F, Peyrot WJ, Baune BT, Breen G, Dehghan A,
et al. (2017): Genetic association of major depression with a typical
features and obesity-related immunometabolic dysregulations. JAMA
Psychiatry 74:1214–1225.
53. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM,
Abdellaoui A, et al. (2018): Genome-wide association analyses identify
44 risk variants and refine the genetic architecture of major depres-
sion. Nat Genet 50:668–681.
54. Polimanti R, Peterson RE, Ong JS, MacGregor S, Edwards AC,
Clarke TK, et al. (2019): Evidence of causal effect of major depression
on alcohol dependence: Findings from the psychiatric genomics
consortium. Psychol Med 49:1218–1226.ournal
